Hologic (NASDAQ:HOLX) Given New $70.00 Price Target at Citigroup

Hologic (NASDAQ:HOLX - Free Report) had its target price decreased by Citigroup from $80.00 to $70.00 in a research note issued to investors on Tuesday,Benzinga reports. Citigroup currently has a neutral rating on the medical equipment provider's stock.

Other equities analysts also recently issued research reports about the company. Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They issued a "peer perform" rating on the stock. UBS Group raised their target price on Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Mizuho decreased their target price on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. William Blair restated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Stephens restated an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Price Performance

HOLX stock traded down $0.22 during mid-day trading on Tuesday, reaching $62.08. 1,870,946 shares of the company's stock were exchanged, compared to its average volume of 2,346,375. The company has a market cap of $13.93 billion, a price-to-earnings ratio of 19.58, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The stock's 50 day moving average is $68.77 and its 200 day moving average is $75.64. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic has a 12-month low of $61.70 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts expect that Hologic will post 4.28 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. FMR LLC boosted its holdings in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Norges Bank purchased a new stake in shares of Hologic during the fourth quarter worth about $133,414,000. Boston Partners increased its position in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. Champlain Investment Partners LLC purchased a new stake in shares of Hologic during the fourth quarter worth about $79,291,000. Finally, Northern Trust Corp grew its stake in Hologic by 26.9% in the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after purchasing an additional 668,086 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.